Yamada T, et al. - This research was designed in order to comparatively gauge the clinical efficacy and safety between biosimilar and originator insulins for the treatment of diabetes. Data did not reveal any significant differences between short-acting biosimilar and originator insulins, including immune reactions. It was discovered that biosimilar insulins could increase the access to modern insulin therapy and reduce medical costs.